louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01642316: The Effect of Washback on Reading Comprehension
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
PHASE3
Conditions: Reading Comprehension
Keywords: washback, reading comprehension
Lead sponsor: Mashhad University of Medical Sciences
Sponsor class: OTHER
First posted: 2012-07-17
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Maximum age (years): 22
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Testing and teaching are completely interrelated in education process; using various kinds of tests teachers are able to anticipate about the strong and weak points of learning in students, their progress and their accomplishment. The influence a test on teaching and learning is commonly referred to as washback. Testing washback is a twisted concept that becomes even more complex under a various interpretations of the washback phenomenon on teaching and learning. This study aimed to describe washback behaviors of students, in the low stakes testing in an ESP environment in two-fold. First, the study investigated the effects of different formative tests on Iranian medical students' English reading comprehension achievement. Secondly, the study explores the effects of washback on the students' attitudes toward English reading comprehension. The pre- and post-tests and one questionnaire were used to collect the data from Iranian medical students. Data were analyzed by paired t-test, t-test, and Mann-Whitney U test.


Eligibility criteria: Inclusion Criteria:

* nursing students
* study at mums

Exclusion Criteria:

* other disciplines
* study at other universities

Primary outcomes:
measure: improving reading comprehension
timeFrame: up to one year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03417024: Automated Breast Ultrasound Case Collection Registry
Official title: Automated Breast Ultrasound Case Collection Registry
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Breast Cancer
Lead sponsor: GE Healthcare
Sponsor class: INDUSTRY
First posted: 2018-01-31
Enrollment: 13
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study will enroll adult women with dense breasts clinically referred for breast cancer screening.

Brief summary: The contribution of automated breast ultrasound (ABUS) to the screening pathway for breast cancer is not fully understood. This prospective study aims to collect longitudinal data in women with dense breasts undergoing ABUS as a supplement to digital breast tomosynthesis (DBT). The data are intended for use in future research on the value and effectiveness of ABUS in routine clinical care.

Data will be collected from eligible women who have been prescribed or have completed DBT and ABUS, screening within a 30-day window. Radiologist evaluations and, when performed, outcomes of biopsy and/or laboratory testing will be recorded. Subjects will be followed for breast cancer status and results of any diagnostic breast exams and/or treatment.


Eligibility criteria: Inclusion Criteria:

1. Are asymptomatic adult women (aged 18 years or older);
2. Are eligible to complete or have completed (within 30 days) screening ABUS and DBT exams per the site standard of care;1
3. Have heterogeneously dense and extremely dense breasts (BI-RADS C or D, respectively) or are determined to have dense breasts prior to the study on initial screening mammography;
4. Are able and willing to participate.

Exclusion Criteria:

1. Have a breast cancer diagnosis (with or without metastasis) or are being treated for breast cancer within the year prior to the study.

Primary outcomes:
measure: Number of Complete Breast Imaging Datasets
timeFrame: Up to 6 Years
Secondary outcomes:
measure: Type of Exams Performed Per Patient
timeFrame: Up to 6 years
measure: Breast Cancer Status
timeFrame: Up to 6 years
Other outcomes:
Locations:
city: Chicago
country: United States
facility: The University of Chicago
state: Illinois
Study officials:
References:
Clinical trial NCT02620124: GnRH Agonist as Luteal Support in FET Cycles
Official title: GnRH Anonist as Luteal Support in Frozen-thawed Embryo Transfer Cycles
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Infertility
Lead sponsor: Turku University Hospital
Sponsor class: OTHER_GOV
First posted: 2015-12-02
Enrollment: 100
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Back ground: A single dose of GnRH analogue in the luteal phase is reported to improve the outcome of IVF/ICSI treatments but the effect in FET cycles has not been reported.

Aim: To compare the results of frozen thawed embryo transfers with and without GnRHa analogue support Primary end point: IR, PR, on going PR Secondary end point: hCH, E2 and progesterone levels 14 days after thawing


Eligibility criteria: Inclusion Criteria:

* 20 - 45 year old women comig to frozen thawed embryo transfer

Exclusion Criteria:

* The age of the woman over 42 years during the initial ICF/ICSI- treatment from which the embryos derive
* Abnormal uterus
* Known abnormality of karyotype of the woman or her partner
* Severe male factor as an exclusive reason for subfertility
* Allegy for triptorelin acetate

Primary outcomes:
measure: Pregnancy rate
timeFrame: five weeks after the embryo transfer
measure: Implantation rate
timeFrame: five weeks after the embryo transfer
measure: Ongoing pregnancy rate
timeFrame: ten weeks after the embryo transfer
Secondary outcomes:
measure: hCG- level
timeFrame: 14 days after thawing of the embryos
Other outcomes:
Locations:
Study officials:
affiliation: Hospital District of the South-West Finland
name: Varpu Jokimaa, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00947024: To Demonstrate the Effect of Food on the Bioavailability of Glipizide
Official title: The Effect of Food on the Bioavailability of Glipizide
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Type 2 Diabetes
Lead sponsor: Sandoz
Sponsor class: INDUSTRY
First posted: 2009-07-27
Enrollment: 18
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To demonstrate the effect of food on the bioavailability of Glipizide.


Eligibility criteria: Inclusion Criteria:

* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

* Positive test results for HIV or hepatitis B or C.
* Treatment for drug or alcohol dependence.

Primary outcomes:
measure: Bioequivalence based on AUC and Cmax
timeFrame: 15 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Novum Pharmaceutical Research Services
name: Roger D. Anderson, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01977924: Impact of Polyphenols on Endothelial Function in Obstructive Sleep Apnea
Official title: Impact of Polyphenols on Endothelial Function in Obstructive Sleep Apnea: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Obstructive Sleep Apnea
Keywords: sleep apnea
polyphenols
endothelial function
Lead sponsor: University Hospital, Angers
Sponsor class: OTHER_GOV
First posted: 2013-11-07
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Severe obstructive sleep apnea (OSA) is associated with increased cardiovascular morbidity and mortality. Endothelial dysfunction, an early marker of vascular disease has been demonstrated in OSA. Regular treatment of OSA by continuous positive airway pressure (CPAP) improves endothelial function and is associated with a reduction in cardiovascular risk. Approximately 40% of patients with OSA are intolerant or insufficiently adherent to CPAP. Alternative treatments or adjuvants to the CPAP are needed.

The polyphenols have demonstrated their effectiveness in improving endothelial function in patients with CV disease. No randomized controlled studies have evaluated the impact of PPR on the endothelial dysfunction associated with OSAHS.

Detailed description: The endpoint is the change to one month of polyphenols treatment of the endothelial function measured by the index of hyperemic reactivity.

The secondary endpoints are changes at one month of supplementation with polyphenols of ambulatory blood pressure measurement in 24 hours (MAPA), micro-circulatory responsiveness, the speed of the pulse wave and biological measurements (lipid profile, blood glucose, fasting insulin, leptin, adiponectin, hs-CRP, 8-isoprostane levels and cellular origin of microparticles).

Eligibility criteria: Inclusion Criteria:•

* apnea hypopnea index \> 30
* accepting polyphenols supplementation
* Signed informed consent

Exclusion Criteria:

* Epworth sleepiness scale \> 16/24
* Severe cardiac and/or respiratory disease
* BMI\>35 kg/m2
* Anemia

Primary outcomes:
measure: endothelial function measured by the index of hyperemic reactivity
timeFrame: one month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Trzepizur W, Bironneau V, Recoquillon S, Priou P, Meslier N, Hamel JF, Henni S, Darsonval A, Messaoudi K, Martinez MC, Andriantsitohaina R, Gagnadoux F. Polyphenols Have No Impact on Endothelial Function in Patients with Obstructive Sleep Apnea: A Randomized Controlled Trial. J Nutr. 2018 Apr 1;148(4):581-586. doi: 10.1093/jn/nxy005.
Clinical trial NCT01734824: Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo
Official title: Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE4
Conditions: Bone Marrow Oedema Syndrome
High Turnover Bone Disease
Quality of Life
Keywords: bone marrow edema, denosumab, PTH 1-84
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2012-11-28
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The etiology of bone marrow edema (BME) is still uncertain. Several studies report therapeutic success with antiresorptive drugs.

This study investigates antiresorptive and osteoanabolic drugs versus placebo in BME

Detailed description: Patients are assigned to receive either denosumab 60mg sc (once) or placebo or daily teriparatide sc for three months or placebo.

MRI examinations at baseline and after three months will be performed. Serum bone turnover markers will be evaluated as well as QoL questionnaires.

Eligibility criteria: Inclusion Criteria:

* MRI diagnosed bone marrow edema

Exclusion Criteria:

* any prior antiresorptive or osteoanabolic treatment
* any prior therapy with strontium ranelate
* Hyper-/hypocalcemia
* malignancies
* pregnancy
* and contraindication against denosumab or teriparatide

Primary outcomes:
measure: Reduction/termination of bone marrow edema with antiresorptive and osteoanabolic drugs
timeFrame: baseline - month 1 - month 3
Secondary outcomes:
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Medical University Vienna - St. Vincent Hospital
Study officials:
affiliation: Medical University of Vienna
name: Christian Muschitz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06764524: Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care Management
Official title: Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care Management
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Hairy Cell Leukemia (HCL)
Lead sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Sponsor class: OTHER
First posted: 2025-01-08
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population will be composed by Hairy Cell Leukemia patients (3 groups: patients at diagnosis (n=10); patients in complete response for \>2 years (n=10); relapsed patients meeting treatment indications (n=5)) and by Healthy Donors (n=25) enrolled among volunteers of the no profit organization BolognAIL.

Brief summary: Check whether patients with Hairy Cell Leukemia (HCL) of different status (at diagnosis, in complete remission \> 2 years or relapsed requiring therapy) have a 'signature' of altered immunity based on extracellular vesicles (EV)

Detailed description: Extracellular vesicles are small particles detected within plasma and recognized as mediators of intercellular communication thanks to their cargo of proteins, lipids, and nucleic acids. However, the composition of vesicles from Hairy Cell Leukemia patients, which may hold the key to unraveling their involvement and function within tumor microenvironment, is totally unknown. The aim of this study is to characterize these extracellular vesicles in order to identify biology-related and disease-specific biomarkers.

Eligibility criteria: Inclusion criteria for patients:

* WHO2022-defined diagnosis of Hairy Cell Leukemia.
* age ≥18 years.
* signed informed consent.

Inclusion criteria for Healthy Donors:

* age ≥18 years.
* Volunteers in general good health, free from any disease or serious illness.
* Signed informed consent.

Exclusion criteria

- None

Primary outcomes:
measure: Extracellular vesicle characterization
timeFrame: 2 years
Secondary outcomes:
measure: Extracellular vesicles' functions and biomarker validation
timeFrame: 2 years
Other outcomes:
Locations:
city: Bologna
country: Italy
facility: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Study officials:
affiliation: IRCCS Azienda Ospedaliero-Universitaria di Bologna
name: Lucia Catani, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03339024: Intranasal Oxytocin Effects in Alcohol Withdrawal and Dependence; Follow-up Study
Official title: Long-term Effects of Intranasal Oxytocin in Alcohol Withdrawal and Dependence: Follow-up of a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Alcoholism
Substance-Related Disorders
Keywords: Oxytocin
Administration, Intranasal
Ethanol
Follow-up Studies
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
Collaborators: name: St. Olavs Hospital
name: Lade Addiction Treatment Center
First posted: 2017-11-09
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is an assessment of the long-term effect of oxytocin nasal spray on alcohol withdrawal and dependence in adults admitted for detoxification of alcohol after 60 days and 1 year. It is a follow-up study of a placebo-controlled randomized controlled study where subjects used oxytocin nasal spray during acute withdrawal and the following 4 weeks in an outpatient setting. Half of the participants have received oxytocin nasal spray, the other half placebo nasal spray (NCT02903251). (added March 2019: 24 patients were available for 1-year follow-up)


Eligibility criteria: Inclusion Criteria:

* participants in the RCT (NCT02903251) who completed the study

Exclusion Criteria:

* participants in the RCT (NCT02903251) who did not complete the study

Primary outcomes:
measure: Alcohol intake
timeFrame: 60 days
measure: Alcohol intake
timeFrame: 1 year
Secondary outcomes:
measure: Sleep
timeFrame: 60 days
measure: Sleep
timeFrame: 1 year
measure: Number of rehospitalisations and readmissions to treatment for substance use disorders
timeFrame: 1 year
Other outcomes:
Locations:
city: Trondheim
country: Norway
facility: Lade Addiction Treatment Center
Study officials:
affiliation: Norwegian University of Science and Technology
name: Olav Spigset, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Melby K, Fasmer OB, Henriksen TE, Grawe RW, Aamo TO, Spigset O. Actigraphy assessment of motor activity and sleep in patients with alcohol withdrawal syndrome and the effects of intranasal oxytocin. PLoS One. 2020 Feb 13;15(2):e0228700. doi: 10.1371/journal.pone.0228700. eCollection 2020.
Clinical trial NCT06002724: Feasibility Study of Peripheral Venous Cannulation Pain in Predicting Acute Pain After Total Knee Arthroplasty
Official title: Feasibility Study of Peripheral Venous Cannulation Pain in Predicting Acute Pain After
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Venous Cannulation Pain
Total Knee Arthroplasty
Movement-evoked Pain
Acute Pain
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
First posted: 2023-08-21
Enrollment: 180
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing unilateral total knee arthroplasty for the first time under general anesthesia combined with nerve block

Brief summary: The goal of this prospective observational study is to explore the feasibility of preoperative peripheral venous cannulation pain score in predicting acute pain after total knee arthroplasty, including resting pain and movement-evoked pain.


Eligibility criteria: Inclusion Criteria:

1. Patients undergoing the first unilateral total knee arthroplasty surgery under general anesthesia combined with nerve block ;
2. Age : 18 years old ≤ age ≤ 80 years old ;
3. ASA grade I-II ;
4. Informed consent was signed by patients or immediate family members before operation.

Exclusion Criteria:

1. There are known pain abnormalities, mental disorders, cognitive dysfunction ;
2. patients with long-term use of opioids and a history of drug dependence ;
3. patients with alcohol dependence ;
4. the patient refused to use the analgesic pump ;
5. Difficult to understand the VAS score ;
6. body mass index ≥ 40 ;
7. hand nerve abnormalities, hand loss ;
8. plan postoperative ICU patients ;
9. In other cases, the researchers believe that is not suitable for this researcher.

Primary outcomes:
measure: postoperative resting pain and movement-evoked pain
timeFrame: one hour、the first day and the second day after operation
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01422824: An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) as Maintenance Treatment in Patients With Chronic Renal Anemia on Haemodialysis
Official title: An Observational. Non-interventional Study to Observe the Safety and Efficacy of MIRCERA in the Treatment of Chronic Renal Anemia in Maintenance ESA Treated Patients on Haemodialysis (STABILE)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anemia, Kidney Disease, Chronic
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2011-08-24
Enrollment: 185
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with chronic renal anemia on haemodialysis in maintenance ESA treatment

Brief summary: This prospective observational study will evaluate the safety and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in patients with chronic renal anemia on haemodialysis in maintenance ESA treatment. Data will be collected from patients receiving once monthly Mircera according to standard of care and local labelling during 12 months of treatment.


Eligibility criteria: Inclusion Criteria:

* Adult patients, \>/= 18 years of age
* Stage IV chronic kidney disease, on haemodialysis
* Chronic renal anemia, on maintenance ESA treatment
* Hemoglobin concentration between 10.0 an 12 g/dL
* Continuous maintenance epoetin therapy with the same dosing interval during the previous month

Exclusion Criteria:

* Contraindications to ESA treatment (e.g. hypersensitivity, non-controlled hypertension)
* Hemoglobinopathies (e.g. homozygous sickle-cell disease, thalassemia of all types)
* Anemia due to hemolysis, pure red cell aplasia

Primary outcomes:
measure: Number of Participants With Adverse Events (AEs)
timeFrame: Up to 12 months
Secondary outcomes:
measure: Hemoglobin Levels
timeFrame: Baseline; Weeks 8, 16, 24, 48
Other outcomes:
Locations:
city: Delcevo
country: Macedonia, The Former Yugoslav Republic of
city: Prilep
country: Macedonia, The Former Yugoslav Republic of
city: Skopje
country: Macedonia, The Former Yugoslav Republic of
city: Stip
country: Macedonia, The Former Yugoslav Republic of
city: Struga
country: Macedonia, The Former Yugoslav Republic of
city: Strumica
country: Macedonia, The Former Yugoslav Republic of
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT01424124: Safety and Efficacy of YHD001 in Asthma
Official title: Randomized, Double-blind, Placebo/Active-controlled, Multi-center Clinical Trial to Investigate the Safety/Tolerability and Efficacy of YHD001 Following 8 Weeks Oral Administration of YHD001 in Patients With Partially Controlled Asthma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Asthma
Lead sponsor: Yuhan Corporation
Sponsor class: INDUSTRY
First posted: 2011-08-26
Enrollment: 56
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main objective is to evaluate the safety/tolerability and efficacy of YHD001 compared to singulair or placebo in patients (n=96) with partially controlled asthma.

The study will conduct with 4 comparative groups orally treated with YHD001 dose level 1(t.i.d.), YHD001 dose level 2(t.i.d.), singulair 10mg(q.d.) or Placebo for 8 weeks.

Detailed description: Singulair: Montelukast sodium (leukotriene modulator)

Eligibility criteria: Inclusion Criteria:

* Provision of signed written informed consent
* Acceptable medical history, physical exam,laboratory tests and EKG, during screening
* Nonsmoking (for longer than 1 year) patients with asthma
* Reversible airways obstruction (an increase in FEV1 absolute value of 12% or greater) 20 to 30 minutes after inhalation of b-agonist
* FEV1 between 50% and 85% of the predicted value (withholding short-acting, inhaled b2-adrenergic agonist for 6 hours)

Exclusion Criteria:

* History of any clinically significant disease
* History of drug/chemical/alcohol abuse
* Active upper respiratory tract infection within 3 weeks, emergency room treatment for asthma within 1 month, or hospitalization for asthma within 3 months of the prestudy visit

Primary outcomes:
measure: Change from baseline of FEV1 at week 4
timeFrame: Baseline, week 4
Secondary outcomes:
measure: Change from baseline of FEV1 at week 8
timeFrame: Baseline, week 8
measure: Change from baseline of PEFR at week 8
timeFrame: Baseline, week 8
measure: Change from baseline of ACT Score at week 8
timeFrame: Baseline, week 8
measure: Change from baseline of using rescue medication(b-Agonist) at week 8
timeFrame: Baseline, week 8
measure: safety assessment
timeFrame: week 9
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References: